Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Renovo Slashes Jobs After Trial Failure

by Michael McCoy
March 14, 2011 | A version of this story appeared in Volume 89, Issue 11

Renovo is reducing its staff by more than 100 people after negative Phase III clinical trial results for Juvista, an injectable solution of human active recombinant transforming growth factor β3 being developed to reduce scarring. Renovo, based in Manchester, England, employs about 110 people. The firm announced the trial results on Feb. 11. The decision to downsize is in response to a review of the results and confirmation that Shire, its commercialization partner for Juvista, has terminated a licensing agreement for the product.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.